If you live in Allegheny County, you have probably seen a Narcan vending machine. You have probably read about overdoses in your neighborhood, or heard about them at work, at church, or from your kid’s friend’s parents. You have probably noticed, over the past few years, that the conversation about fentanyl has stopped sounding like distant news and started sounding like your zip code.
Pennsylvania consistently ranks among the top U.S. states for overdose mortality. The Pennsylvania Department of Health’s overdose data and Allegheny County Health Department dashboards have, for years, documented one of the country’s most concentrated opioid crises. Western Pennsylvania in particular has been hit hard: first by prescription opioids, then by heroin, then by fentanyl, and now by fentanyl mixed with xylazine, a veterinary sedative that has changed the medical picture of what families are dealing with.
This is a guide for Pittsburgh-area families, and Pennsylvania families more broadly, who are watching someone they love and trying to figure out what to do next. It is written by a clinician, not a marketer. It will not pretend the situation is less serious than it is. It will also not catastrophize. It will give you the clinical picture, the family decision framework, and a clear path forward if you decide to act.
The State of Fentanyl in Pennsylvania
The pattern in Pennsylvania has moved through four phases over the past fifteen years.
The first phase was the prescription opioid era, when Pennsylvania, particularly western Pennsylvania with its industrial and post-industrial communities, saw widespread prescription of OxyContin and related medications, often for chronic pain following work injuries. Many of the people now in their thirties and forties who are dealing with opioid use disorder began their use during this period, with a legitimate prescription.
The second phase was the heroin era, beginning around 2010, when prescription supply tightened and many people transitioned to street heroin. Pittsburgh and Philadelphia became significant heroin markets.
The third phase, which began around 2015 and continues, is the fentanyl era. Fentanyl is synthetic, cheap to produce, and substantially more potent than heroin. It has nearly replaced heroin in the Pennsylvania supply. Many people who think they are using heroin are using fentanyl.
The fourth phase, the one we are in now, is the xylazine era. Xylazine (“tranq”) is a veterinary sedative that has been increasingly mixed into the fentanyl supply, particularly in Philadelphia first and now across Pennsylvania. According to the U.S. Drug Enforcement Administration’s xylazine threat update, the contamination is widespread enough that it has been formally designated an emerging threat to public health.
Xylazine matters clinically for several reasons that families need to understand:
Xylazine does not respond to Narcan. Naloxone reverses opioid overdoses by blocking opioid receptors. Xylazine is not an opioid. In a mixed overdose, Narcan will reverse the fentanyl component but not the xylazine component, meaning the person may remain unresponsive even after Narcan is administered.
Xylazine changes the withdrawal picture. Xylazine causes its own withdrawal syndrome, which is different from opioid withdrawal and which most addiction treatment facilities have only recently developed protocols for.
Xylazine causes skin wounds. Long-term xylazine exposure is associated with severe skin ulcers, often on areas where the substance is repeatedly injected but sometimes on other parts of the body. These wounds do not heal normally and require specialized care.
Xylazine produces extreme sedation. People exposed to xylazine often experience prolonged, deep sedation that is difficult to rouse them from. This can look like a sustained overdose state even when not technically lethal.
Allegheny County has been seeing rising xylazine detection in its drug supply over the past two years. If you are a Pittsburgh-area family, this is information that affects how you think about risk, how you think about timing, and how you think about treatment placement.
For information specific to the Crosswell intervention model in the region, see a professional drug and alcohol interventionist serving Pittsburgh families.
Why Pittsburgh Is Different
Pittsburgh is unusual among American cities for having developed one of the country’s most robust harm reduction infrastructures. Prevention Point Pittsburgh, the Allegheny County Health Department, and a network of community organizations have built a model that has saved a substantial number of lives through naloxone distribution, syringe service programs, and other harm reduction interventions.
This is a real and important strength. Harm reduction works. The data on it is clear, and the people doing this work are not the problem.
But harm reduction is designed to keep people alive, not to initiate treatment. It serves a specific and important function: reducing the immediate lethal risk of active use while preserving the possibility that the person can later choose recovery. It is not, and was never designed to be, a substitute for treatment engagement.
This matters for families because there is a quiet assumption that often settles into Pittsburgh-area families: that if our loved one is using, the harm reduction system will catch them, will keep them alive, will hand them off to treatment when they’re ready.
The harm reduction system can keep them alive in any given overdose event. It cannot put them into treatment. That step, from “alive” to “engaged in recovery,” almost always requires either the person themselves to initiate, or the family, or both. In the xylazine era, with naloxone less reliably effective, the assumption that the harm reduction system is a sufficient backstop has become harder to defend.
This is not an argument against harm reduction. It is an argument for not letting harm reduction be the only line of defense. Family intervention is the other line.
Recognizing Opioid Use in a Loved One
The signs of opioid use have become, over time, more familiar to American families. Pinpoint pupils. Slowed breathing. Drowsiness in inappropriate contexts. Nodding off. Constipation. Weight loss. Hygiene neglect. Withdrawal symptoms when use is interrupted, including sweating, restlessness, leg cramps, runny nose, diarrhea, and vomiting.
The behavioral patterns are similarly recognized: financial issues that don’t add up, missing items in the home that were valuable enough to sell, withdrawal from family events, new social circles that aren’t introduced, encrypted messaging apps appearing on phones, and unusual payment-app activity.
What is newer, and what Pennsylvania families specifically need to understand, are the signs that suggest xylazine exposure on top of fentanyl:
- Skin lesions or wounds that don’t heal normally, particularly but not exclusively at injection sites
- Episodes of extreme sedation, including sleeping for very long stretches and difficulty being roused
- Past overdose where Narcan only partially worked
- Use of the term “tranq” or “tranq dope” in their conversations or messages
- Friends or contacts who have been hospitalized recently for wounds related to drug use
The Narcan question deserves direct address. Finding Narcan in your loved one’s possession used to be a reassuring sign. It meant they were prepared. In the current Pennsylvania supply environment, finding Narcan is more accurately read as a sign that they know their supply carries overdose risk and that they or their social circle have experienced overdoses recently. It is not reassurance. It is information.
For Philadelphia-area families seeing similar patterns, intervention support for Philadelphia families follows the same clinical framework.
The Pennsylvania Treatment Landscape
Pennsylvania has a large and varied treatment system. The decision of where to send a loved one after a successful intervention is rarely simple, and the right answer depends on the specifics of the case.
The general framework most clinicians use:
In-state treatment has the advantages of geographic proximity (family can visit, family can be involved in treatment), familiarity with regional patterns, and existing networks for aftercare. The Pennsylvania Department of Drug and Alcohol Programs maintains a directory of state-licensed providers.
Out-of-state treatment has the advantages of geographic separation from the supply network, distance from the relationships and routines that have organized around use, and access to specialized programs that may not exist locally. For people with serious treatment-resistant histories, out-of-state placement is often clinically appropriate.
For Pittsburgh families specifically, common patterns include placement in specialized programs in Florida, Arizona, California, Texas, and Tennessee, depending on case specifics. The clinical question is not “where is best in general.” It’s “where is best for this specific person at this specific time.”
Sober transport, getting the person safely from the family meeting to the treatment intake, matters more in Pennsylvania than in some other regions because the supply density is high. The window between “yes” and “in the program” is the highest-risk window for relapse-driven refusal, and it gets riskier when the person remains in their familiar environment during that window. Professional sober transport addresses this directly.
What a Professional Intervention Looks Like
When most families picture an “intervention,” they are picturing the television show. They are picturing a confrontational meeting where family members read prepared statements, present ultimatums, and the person at the center either accepts treatment in tears or refuses and storms out.
That model exists. It is also substantially outdated, both clinically and in practice.
The contemporary model, what we use at Crosswell and what most clinically-rigorous interventionists use, is structured around lower confrontation, longer preparation, and more sophisticated family-system work. The Crosswell Method has five phases:
Listening. Multiple sessions with the family, often spanning two to four weeks. We map the family system, understand the history of use, document past attempts, identify the family roles that have organized around the crisis, and learn the specific person we will be working with. This phase produces the clinical understanding that everything else is built on.
Invitation. A structured family conversation, not an ambush. The person is invited into a conversation framed around concern, not accusation. The language, the sequence, and the pacing are designed to reduce the shame response that triggers refusal. Trauma-informed framing matters here. Most people with serious opioid use disorder have significant trauma history, and confrontational models predictably amplify the trauma response.
Planning. Treatment placement is confirmed in advance. We do not run an intervention without a confirmed bed. Travel is arranged. The family has a clear plan for the case where the person says yes and a clear plan for the case where they say no.
Treatment Transition. Sober transport from the family meeting to the treatment intake. Clinical handoff to the receiving team. This phase has its own clinical importance. The first 72 hours after an intervention is the highest-risk window for the “yes” to disappear.
Ongoing Family Support. The work continues after the person is in treatment. Family recovery coaching, clinical case management, preparation for the eventual return home. In Pennsylvania cases specifically, this often includes coordination across multiple providers and family members spread across the region.
A trauma-informed intervention reduces resistance rather than increasing it. The clinical research on family engagement, including the well-documented CRAFT (Community Reinforcement and Family Training) model research summarized by the National Institute on Drug Abuse, supports this consistently.
When to Act vs. When to Plan
The question I am asked most often by Pennsylvania families is some version of: “Is it time yet?”
The honest answer is that the threshold for “yet” has lowered substantially over the past decade, primarily because of the supply environment. The clinical framework I use with families:
This week, not next month, if any of these are present:
- A recent overdose, whether they admit it or not
- A recent ER visit related to substance use
- Mention of xylazine, “tranq,” or skin wounds appearing
- Active suicidal statements
- Escalating use in the last 60 days
- Loss of housing, primary relationship, or employment in the last 90 days
- They have started carrying Narcan
- A friend in their circle has recently overdosed or died
Begin serious planning if:
- You are seeing multiple behavioral patterns consistent with active use
- Their social network has shifted entirely in the last six to twelve months
- Financial issues are recurring and unexplained
- Family members are showing stress symptoms (sleep, health, anxiety)
- Past attempts at conversation have produced denial or anger
- You no longer trust their account of their own life
Call 911, not an interventionist, if:
- They are unresponsive or showing slowed breathing now
- They have stated active intent to end their life
- They are showing signs of overdose (slowed breathing, blue lips, unresponsiveness)
- They are in psychiatric crisis with imminent danger
The bias in family decision-making, across every case I have worked, is toward waiting too long, not acting too soon. The reasons for that bias are understandable (fear of making it worse, fear of being wrong, hope that things will improve on their own), but they have to be measured against the actual risk environment, which has changed. The CDC’s overdose mortality data provides the national context for what that risk environment now looks like.
Frequently Asked Questions
Is xylazine in Pittsburgh’s drug supply?
Yes. Allegheny County Health Department surveillance and Pennsylvania Department of Health data have documented increasing xylazine detection in Western Pennsylvania over the past two years. It is widespread enough that families should consider it part of the baseline risk for anyone using street opioids.
Can a family stage an intervention if their loved one has overdosed before?
Yes. Past overdose is actually one of the strongest clinical indicators that intervention is appropriate. The clinical framing changes (the family’s emotional state often shifts after an overdose event, which can make the conversation more difficult), but the case for intervention is stronger, not weaker.
Should we send them to treatment in Pennsylvania or out of state?
This is a case-by-case decision and one we work through with the family in the Planning phase. Factors include the person’s history (have they tried local treatment before?), the local supply network, the specific clinical needs (does this case need specialized care that isn’t available locally?), and the family’s geographic situation. There is no universal answer.
Will the intervention work if they’ve refused treatment before?
Past refusal is common in cases where families end up calling a professional. Most people who eventually accept treatment have refused it at some prior point. A professional intervention is specifically designed for the case where less structured family efforts have not worked.
Can you intervene if they don’t live with the family?
Yes. Many of the cases we work involve a person who lives independently, sometimes in a different city or state from the family. The intervention model is built around the family system regardless of physical proximity, and the logistics of bringing the family together for the conversation can be arranged.
Do interventionists work with Medicaid or insurance?
Interventions themselves are typically not covered by insurance. The treatment placement that follows an intervention is often covered, and treatment placement coordination is part of what we manage. We discuss the financial picture transparently in the initial consultation.
What if my loved one is also dealing with depression or PTSD?
This is common. Co-occurring mental health conditions are present in the majority of substance use disorder cases. A clinically trained interventionist is appropriate for these cases specifically because the work requires understanding both the substance use and the underlying mental health picture. In some cases, the primary intervention focus becomes mental health rather than substance use, and a mental health intervention may be appropriate alongside addiction support.
Conclusion
The fentanyl-and-xylazine era in Pennsylvania has changed the cost of waiting. The clinical model that was built around “wait until they’re ready” was built for a different supply environment and a slower clinical reality. The contemporary model, structured, non-confrontational, trauma-informed, family-system-aware, is built for the situation Pennsylvania families are actually in.
If you are reading this because you are watching someone you love and trying to figure out the right next step, the most useful action is usually a single conversation with a clinician who can give you a clear-eyed assessment of where you are and what timing actually looks like in your case. It does not commit you to anything.
We work with families across Pennsylvania (Pittsburgh, Philadelphia, Erie, Scranton, Harrisburg, the smaller communities) and across the country. For statewide context, see intervention services across Pennsylvania.
About the Author
Will Crosswell is a Licensed Clinical Social Worker (LCSW), Licensed Chemical Dependency Counselor (LCDC), and EMDR-trained clinician with more than ten years of experience helping families navigate addiction and mental health crises. Crosswell Interventions is independent and does not accept referral fees from treatment facilities, operating as an advocate for the families it serves rather than for any treatment program.
